ResearcherUniversity of WürzburgNo recent work listed
Ingo Klein
Matched on ORCID iD 0000-0003-1097-0986; OpenAlex author ID A5101682717. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 3
- Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
- Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
- Prognostic impact of simultaneous venous resections during surgery for resectable pancreatic cancer. Last author DOI 10.1016/j.hpb.2019.12.017↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Volker Kunzmann · 3 shared papers, 2020–2023 · strength 0.31
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Prognostic impact of simultaneous venous resections during surgery for resectable pancreatic cancer. DOI 10.1016/j.hpb.2019.12.017↗
- Paper Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in… DOI 10.1016/s2468-1253(20)30330-7↗
- Thomas Jens Ettrich · 2 shared papers, 2021–2023 · strength 0.20
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in… DOI 10.1016/s2468-1253(20)30330-7↗
- Helmut Friess · 2 shared papers, 2021–2023 · strength 0.20
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in… DOI 10.1016/s2468-1253(20)30330-7↗
- Hana Algül · 2 shared papers, 2021–2023 · strength 0.20
- Paper Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized p… DOI 10.1016/j.annonc.2022.09.161↗
- Paper Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in… DOI 10.1016/s2468-1253(20)30330-7↗
- Eike Gallmeier · 1 shared paper, 2023 · strength 0.12
- Jasmin Schuhbaur · 1 shared paper, 2023 · strength 0.12
- Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.12
- Andrea Tannapfel · 1 shared paper, 2023 · strength 0.12
- Waldemar H. Uhl · 1 shared paper, 2023 · strength 0.12
- Michael Geißler · 1 shared paper, 2023 · strength 0.12
- Detlef Klaus Bartsch · 1 shared paper, 2023 · strength 0.12
- S Daum · 1 shared paper, 2023 · strength 0.12
- Manfred Paul Lutz · 1 shared paper, 2023 · strength 0.12
- Alexander Kleger · 1 shared paper, 2023 · strength 0.12
- Thomas Theodor Werner Seufferlein · 1 shared paper, 2023 · strength 0.12
- Anke Reinacher‐Schick · 1 shared paper, 2023 · strength 0.12
- Alexander Otto König · 1 shared paper, 2023 · strength 0.12
- Uwe A. Wittel · 1 shared paper, 2023 · strength 0.12
- Angelika M. R. Kestler · 1 shared paper, 2023 · strength 0.12
- Margaret A. Tempero · 1 shared paper, 2023 · strength 0.12
- Marko Kornmann · 1 shared paper, 2023 · strength 0.12
- Christiane J. Bruns · 1 shared paper, 2023 · strength 0.12
- Lukas Perkhofer · 1 shared paper, 2023 · strength 0.12
- Friedrich Anger · 1 shared paper, 2020 · strength 0.11
- Marcus Bahra · 1 shared paper, 2021 · strength 0.08
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.